SEARCH

SEARCH BY CITATION

References

  • Bauer B., Hartz A. M., Fricker G. and Miller D. S. (2004) Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol. Pharmacol. 66, 413419.
  • Bauer B., Yang X., Hartz A. M., Olson E. R., Zhao R., Kalvass J. C., Pollack G. M. and Miller D. S. (2006) In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol. Pharmacol. 70, 12121219.
  • Bauer B., Hartz A. M. and Miller D. S. (2007) Tumor necrosis factor α and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol. Pharmacol. 71, 667675.
  • Bortman P., Folgueira M. A., Katayama M. L., Snitcovsky I. M. and Brentani M. M. (2002) Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: a mini review. Braz. J. Med. Biol. Res. 35, 19.
  • Chan G. N., Hoque M. T., Cummins C. L. and Bendayan R. (2011) Regulation of P-glycoprotein by orphan nuclear receptors in human brain microvessel endothelial cells. J. Neurochem. 118, 163175.
  • Chow E. C., Maeng H. J., Liu S., Khan A. A., Groothuis G. M. and Pang K. S. (2009) 1α,25-Dihydroxyvitamin D3 triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo. Biopharm. Drug Dispos. 30, 457475.
  • Chow E. C., Sun H., Khan A. A., Groothuis G. M. and Pang K. S. (2010) Effects of 1α,25-dihydroxyvitamin D3 on transporters and enzymes of the rat intestine and kidney in vivo. Biopharm. Drug Dispos. 31, 91108.
  • Chow E. C., Durk M. R., Cummins C. L. and Pang K. S. (2011) 1α,25-Dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo. J. Pharmacol. Exp. Ther. 337, 846859.
  • Cirrito J. R., Deane R., Fagan A. M. et al. (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J. Clin. Invest. 115, 32853290.
  • Coty W. A. (1980) A specific, high affinity binding protein for 1α,25-dihydroxy vitamin D in the chick oviduct shell gland. Biochem. Biophys. Res. Commun. 93, 285292.
  • Deane R., Wu Z. and Zlokovic B. V. (2004) RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid β-peptide clearance through transport across the blood-brain barrier. Stroke 35, 26282631.
  • DeLuca H. (1976) Metabolism of vitamin D: current status. Am. J. Clin. Nutr. 29, 12581270.
  • Doran A., Obach R. S., Smith B. J. et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos. 33, 165174.
  • Echchgadda I., Song C. S., Roy A. K. and Chatterjee B. (2004) Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction by the vitamin D receptor. Mol. Pharmacol. 65, 720729.
  • Eloranta J. J., Zair Z. M., Hiller C., Hausler S., Stieger B. and Kullak-Ublick G. A. (2009) Vitamin D3 and its nuclear receptor increase the expression and activity of the human proton-coupled folate transporter. Mol. Pharmacol. 76, 10621071.
  • Eloranta J. J., Hiller C., Juttner M. and Kullak-Ublick G. A. (2012) The SLCO1A2 gene, encoding human organic anion-transporting polypeptide 1A2, is transactivated by the vitamin D receptor. Mol. Pharmacol. 82, 3746.
  • Fan J., Liu S., Du Y., Morrison J., Shipman R. and Pang K. S. (2009) Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1α,25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer. J. Pharmacol. Exp. Ther. 330, 389402.
  • Gray R. W., Omdahl J. L., Ghazarian J. G. and DeLuca H. F. (1972) 25-Hydroxycholecalciferol-1-hydroxylase. Subcellular location and properties. J. Biol. Chem. 247, 75287532.
  • Hartmann T., Bieger S. C., Bruhl B. et al. (1997) Distinct sites of intracellular production for Alzheimer's disease Aβ40/42 amyloid peptides. Nat. Med. 3, 10161020.
  • Hartz A. M., Miller D. S. and Bauer B. (2010) Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-β in a mouse model of Alzheimer's disease. Mol. Pharmacol. 77, 715723.
  • Hoque M. T., Robillard K. R. and Bendayan R. (2012) Regulation of breast cancer resistant protein by peroxisome proliferator-activated receptor α in human brain microvessel endothelial cells. Mol. Pharmacol. 81, 598609.
  • Ito S., Ueno T., Ohtsuki S. and Terasaki T. (2010) Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-β peptide(1–40) in mouse: involvement of an LRP-1-independent pathway. J. Neurochem. 113, 13561363.
  • Ito S., Ohtsuki S., Nezu Y., Koitabashi Y., Murata S. and Terasaki T. (2011) 1α,25-Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-β peptide(1–40) from mouse brain across the blood-brain barrier. Fluids Barriers CNS 8, 20.
  • Jones G. and Tenenhouse H. S. (2002) 1,25(OH)2D, the preferred substrate for CYP24. J. Bone Miner. Res. 17, 179181.
  • Khan A. A., Chow E. C., van Loenen-Weemaes A. M., Porte R. J., Pang K. S. and Groothuis G. M. (2009) Comparison of effects of VDR versus PXR, FXR and GR ligands on the regulation of CYP3A isozymes in rat and human intestine and liver. Eur. J. Pharm. Sci. 37, 115125.
  • Kim R. B. (2002) Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev. 34, 4754.
  • Kim R. B., Fromm M. F., Wandel C., Leake B., Wood A. J., Roden D. M. and Wilkinson G. R. (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101, 289294.
  • Kota B. P., Allen J. D. and Roufogalis B. D. (2011) The effect of vitamin D3 and ketoconazole combination on VDR-mediated P-gp expression and function in human colon adenocarcinoma cells: implications in drug disposition and resistance. Basic Clin. Pharmacol. Toxicol. 109, 97102.
  • Lam F. C., Liu R., Lu P., Shapiro A. B., Renoir J. M., Sharom F. J. and Reiner P. B. (2001) β-Amyloid efflux mediated by p-glycoprotein. J. Neurochem. 76, 11211128.
  • Lee G., Dallas S., Hong M. and Bendayan R. (2001) Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53, 569596.
  • Lowry O. H., Rosebrough N. J., Farr A. L. and Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265275.
  • Maeng H. J., Chapy H., Zaman S. and Pang K. S. (2012) Effects of 1α,25-dihydroxyvitamin D3 on transport and metabolism of adefovir dipivoxil and its metabolites in Caco-2 cells. Eur. J. Pharm. Sci. 46, 149166.
  • Marquez B. and Van Bambeke F. (2011) ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. Curr. Drug Targets 12, 600620.
  • Masoumi A., Goldenson B., Ghirmai S. et al. (2009) 1α,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-β clearance by macrophages of Alzheimer's disease patients. J. Alzheimers Dis. 17, 703717.
  • Miller D. S. (2010) Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol. Sci. 31, 246254.
  • Miller D. L., Papayannopoulos I. A., Styles J., Bobin S. A., Lin Y. Y., Biemann K. and Iqbal K. (1993) Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys. 301, 4152.
  • Miller D. S., Nobmann S. N., Gutmann H., Toeroek M., Drewe J. and Fricker G. (2000) Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol. Pharmacol. 58, 13571367.
  • Mizwicki M. T., Menegaz D., Zhang J., Barrientos-Duran A., Tse S., Cashman J. R., Griffin P. R. and Fiala M. (2012) Genomic and nongenomic signaling induced by 1α,25(OH)2-vitamin D3 promotes the recovery of amyloid-β phagocytosis by Alzheimer's disease macrophages. J. Alzheimers Dis. 29, 5162.
  • Muindi J. R., Peng Y., Potter D. M., Hershberger P. A., Tauch J. S., Capozzoli M. J., Egorin M. J., Johnson C. S. and Trump D. L. (2002) Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin. Pharmacol. Ther. 72, 648659.
  • Narang V. S., Fraga C., Kumar N., Shen J., Throm S., Stewart C. F. and Waters C. M. (2008) Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. Am. J. Physiol. Cell Physiol. 295, C440C450.
  • Ohtsuki S., Ito S. and Terasaki T. (2010) Is P-glycoprotein involved in amyloid-β elimination across the blood-brain barrier in Alzheimer's disease? Clin. Pharmacol. Ther. 88, 443445.
  • Ponchon G., Kennan A. L. and DeLuca H. F. (1969) “Activation” of vitamin D by the liver. J. Clin. Invest. 48, 20322037.
  • Querfurth H. W. and LaFerla F. M. (2010) Alzheimer's disease. N. Engl. J. Med. 362, 329344.
  • Saeki M., Kurose K., Tohkin M. and Hasegawa R. (2008) Identification of the functional vitamin D response elements in the human MDR1 gene. Biochem. Pharmacol. 76, 531542.
  • Schinkel A. H., Smit J. J., van Tellingen O. et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491502.
  • Schmiedlin-Ren P., Thummel K. E., Fisher J. M., Paine M. F., Lown K. S. and Watkins P. B. (1997) Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1α,25-dihydroxyvitamin D3. Mol. Pharmacol. 51, 741754.
  • Slatopolsky E. and Brown A. J. (1997) Vitamin D and its analogs in chronic renal failure. Osteoporos. Int. 7(Suppl 3), S202S208.
  • Thummel K. E., Brimer C., Yasuda K., Thottassery J., Senn T., Lin Y., Ishizuka H., Kharasch E., Schuetz J. and Schuetz E. (2001) Transcriptional control of intestinal cytochrome P-4503A by 1α,25-dihydroxy vitamin D3. Mol. Pharmacol. 60, 13991406.
  • Timsit Y. E. and Negishi M. (2007) CAR and PXR: the xenobiotic-sensing receptors. Steroids 72, 231246.
  • Tirona R. G. and Kim R. B. (2005) Nuclear receptors and drug disposition gene regulation. J. Pharm. Biomed. Anal. 94, 11691186.
  • Tsuji A., Tamai I., Sakata A., Tenda Y. and Terasaki T. (1993) Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem. Pharmacol. 46, 10961099.
  • Wang X., Sykes D. B. and Miller D. S. (2010) Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol. Pharmacol. 78, 376383.
  • Weksler B. B., Subileau E. A., Perriere N. et al. (2005) Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 19, 18721874.
  • Zastre J. A., Chan G. N., Ronaldson P. T., Ramaswamy M., Couraud P. O., Romero I. A., Weksler B., Bendayan M. and Bendayan R. (2009) Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J. Neurosci. Res. 87, 10231036.
  • Zlokovic B. V., Yamada S., Holtzman D., Ghiso J. and Frangione B. (2000) Clearance of amyloid β-peptide from brain: transport or metabolism? Nat. Med. 6, 718.